INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Hôpital Saint-Louis
París, FranciaPublicaciones en colaboración con investigadores/as de Hôpital Saint-Louis (10)
2024
2022
-
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Blood, Vol. 140, Núm. 26, pp. 2773-2787
-
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Blood cancer journal, Vol. 12, Núm. 2, pp. 32
-
MDS-110 SELECT-MDS-1 Trial in Progress: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tamibarotene/Azacitidine Versus Placebo/Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-Positive Higher-Risk MDS
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S303-S304
-
Six-Year Results from RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
Journal of Clinical Oncology
2019
-
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
Blood, Vol. 134, Núm. 5, pp. 421-431
2016
-
European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma
Haematologica
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2013
-
Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma
Haematologica, Vol. 98, Núm. 3, pp. 357-363
2006
-
Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia
Clinical Lymphoma and Myeloma, Vol. 6, Núm. 5, pp. 380-383